NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
10 trialsNCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT01104571 2018-09-17
EPHOS-B
Institute of Cancer Research, United Kingdom
Phase 3 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT03273595 2017-09-06
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT03085368 2017-07-28
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT01283789 2017-02-08
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT01454479 2011-10-19
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Chang Gung Memorial Hospital
Phase 1 Unknown
NCT00842998 2009-06-26
HERLAP
Azienda Ospedaliera Ordine Mauriziano di Torino
Phase 2 Unknown